SCHEMBL21566642

SCHEMBL21566642

Cc1ccc2c(c(C)nn2C)c1C(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 1/20 0.37
▸ ADORA2B P29275 1/20 0.37
▸ PDE6D O43924 1/20 0.33
▸ PDE5A O76074 1/20 0.33
▸ PDE6A P16499 1/20 0.33
▸ PDE6G P18545 1/20 0.33
▸ PDE6B P35913 1/20 0.33
▸ PDE6C P51160 1/20 0.33
▸ PDE6H Q13956 1/20 0.33
▸ MAPK8 P45983 3/20 0.32
▸ MAPK9 P45984 2/20 0.32
▸ MAPT P10636 3/20 0.32
▸ LMNA P02545 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ MAPK10 P53779 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ PDE4A P27815 1/20 0.30
▸ PDE4B Q07343 1/20 0.30
▸ PDE4C Q08493 1/20 0.30
▸ PDE4D Q08499 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25669490 0.77 ADORA2A (0.42) ADORA2AADORA2BPDE6DPDE5APDE6A
SCHEMBL16417281 0.75 MAPK13 (0.38) ADORA2AADORA2BPDE6DPDE5APDE6A
SCHEMBL25700482 0.71 ADORA2A (0.37) ADORA2AADORA2B
SCHEMBL12536276 0.69 MAPK13 (0.42) ADORA2AADORA2BPDE6DPDE5APDE6A
SCHEMBL18538054 0.69 ATM (0.33) LMNA
SCHEMBL16154713 0.68 PDE4A (0.33) PDE6DPDE5APDE6APDE6GPDE6B
SCHEMBL21024170 0.68 CCR4 (0.37) TP53
SCHEMBL18540686 0.67 ADORA2A (0.39) ADORA2AADORA2BMAPK8MAPK9MAPT
SCHEMBL13106166 0.67 ALDH1A1 (0.44) ADORA2AADORA2BMAPTLMNA
SCHEMBL16380219 0.66 ADORA2A (0.42) ADORA2AADORA2BMAPK8MAPK9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190343826-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. 2019-11-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190343826-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 ADORA2A 3882/4885ADORA2B 3757/4885PDE6D 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback